LLY insider trading
HealthcareELI LILLY & Co — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.
About ELI LILLY & Co
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. The company offers cardiometabolic health products, including Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, such as Cyramza for the second-line treatment of gastric cancer or gastro-esophageal junction adenocarcinoma; Erbitux for colorectal cancers and head and neck cancers; Inluriyo for breast cancer; Jaypirca for chronic lymphocytic leukemia or small lymphocytic lymphoma; Retevmo for the treatment of metastatic NSCLC; TYVYT for classic hodgkin's lymphoma; and Verzenio for breast cancer. In addition, the company offers immunology products, which include Ebglyss for severe atopic dermatitis; Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Omvoh for ulcerative colitis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. Further, it provides Emgality for migraine prevention and episodic cluster headache, as well as Kisubla for symptomatic Alzheimer's disease. The company has collaborations with Boehringer Ingelheim Pharmaceuticals, Inc. for the Jardiance product family; and F. Hoffmann-La Roche Ltd and Genentech, Inc. for lebrikizumab, as well as license agreements with Almirall, S.A. for Ebglyss; and Chugai Pharmaceutical Co., Ltd for orforglipron. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.
Company website: www.lilly.com
LLY insider activity at a glance
FilingIQ has scored 2,564 insider transactions for LLY since Jan 28, 2015. The most recent filing in our index is dated May 6, 2026.
Across the full history, 30 open-market purchases
and 1,459 open-market sales
were filed under transaction codes P and S respectively. Compensatory share awards
(code A) and option exercises (code M) are tracked separately and not counted here.
The average FilingIQ composite score on LLY insider trades is 53.6/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.
Other Healthcare tickers with recent insider activity
13F funds holding LLY
Politicians who have traded LLY
Frequently asked
- How many insider trades does FilingIQ track for LLY?
- FilingIQ tracks 2,564 Form 4 insider transactions for LLY (ELI LILLY & Co), covering filings from Jan 28, 2015 onwards. 27 of those were filed in the last 90 days.
- Are LLY insiders net buyers or net sellers?
- Across the full Form 4 history for LLY, 30 transactions (1%) were open-market purchases and 1,459 (57%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
- Where does LLY insider data come from?
- Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
- What sector is LLY in?
- ELI LILLY & Co (LLY) is classified in the Healthcare sector, specifically Drug Manufacturers - General, with a current market capitalisation of $988.62B.
Methodology & sources
Every LLY insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.